Blood And Blood Formation Flashcards

1
Q

Total body distribution of iron

A
Total body iron in an adult is 2.5- 5 g (average 3.5 g)
Men: 50 mg/kg
Women: 38 mg/ kg
It is distributed into:
1. Haemoglobin - 62%
2. Iron stores - 25%
3. Myoglobin - 7%
4. Parenchymal iron (in enzymes,etc) - 6%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

To raise the Hb level of blood by 1g/dl about ___ of elemental iron is needed

A

200mg

Loss of 100 ml of blood (containing 15 g Hb) means loss of 50 mg elemental iron.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

RDA of iron

A

Adult male: 0.5-1 mg
Adult female: 1-2 mg
Pregnancy: 3-5 mg

Infants: 60 μg/kg
Children: 25 μg/kg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Factors facilitating iron absorption

A
  1. Acid
  2. Reducing substances
  3. Meat: by increasing HCI secretion and providing haeme iron
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Factors impeding iron absorption

A
  1. Alkalies: 2 reasons
  2. Phosphates: (rich in egg yolk)
  3. Phytates: (in maize, wheat)
  4. Tetracyclines
  5. Presence of other foods in the stomach.
    In general, bioavailability of iron from cereal based diets is low.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Ferritin curtain and mucosal block

A

The gut has a mechanism to prevent entry of excess iron in the body.
Iron reaching inside mucosal cell is:
1. Transported to plasma
2. Oxidised and complexed with apoferritin to form ferritin
This ferritin generally remains stored in the mucosal cells and is lost when they are shed after 2-4 days
This is called the ‘Ferritin curtain’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Fate of free iron in plasma

A

Free iron is highly toxic.
On entering plasma:
1. Immediately oxidised enzymatically, then
2. Complexed with a glycoprotein transferrin (Tf)
(Total plasma iron content (~3 mg) is recycled 10 times everyday)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Oral iron preparations in brief

A

The preferred route of iron administration is oral.
Dissociable ferrous salts are:
1. Inexpensive
2. Have high iron content
3. Better absorbed than ferric salts, especially at higher doses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Side effects of oral iron preparations

A
  1. Epigastric pain, heartburn, nausea, vomiting, bloating. staining of teeth, metallic taste, colic
  2. Constipation is more common (astringent action) than diarrhoea (irritant action)
  3. May be due to alteration of intestinal flora also

Tolerance to oral iron can be improved by initiating therapy at low dose and gradually increasing to the optimum dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Types of simple oral iron preparations

A
  1. Ferrous sulfate:
    (hydrated 20% iron, dried 32%)
    Cheapest but metallic taste
  2. Ferrous gluconate (12%)
  3. Ferrous fumarate (33% iron):
    Less water soluble than ferrous sulfate and tasteless
  4. Colloidal ferric hydroxide (50% iron)
  5. Carbonyl iron:
    Metallic iron
    Slow absorption and better gastric tolerance
    Low bioavailability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Disadvantages of liquid iron formulations

A

Liquid formulations:

  1. May stain teeth
  2. Should be put on the back of tongue and swallowed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Maximum haematopoietic response is given when

A

A total of 200 mg elemental iron (infants and children 3-5 mg/kg) given daily in 3 divided doses
Prophylactic dose is 30 mg iron daily.
Absorption and side effects are more when given on a empty stomach

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Iron therapy by injection is indicated when

A
  1. Oral iron is not tolerated
  2. Failure to absorb oral iron:
    Chronic inflammation decreases absorption and rate at which iron is utilized.
  3. Non-compliance
  4. In presence of severe deficiency with chronic bleeding.
  5. Along with erythropoietin in CKD patients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Parenteral iron therapy needs calculation of the total iron requirement of the patient for which several formulae have been devised. A simple one is:

A
Iron requirement (mg) =
4.4 x body weight (kg) x Hb deficit (g/dl)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Ionised salts of iron used oral cannot be injected because

A
  1. They have strong protein precipitating action

2. Free iron in plasma is highly toxic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

The organically complexed iron formulations for parenteral route are

A
1. lron-dextran has been in use for long
Two relatively new ones:
2. Ferrous sucrose
3. Ferric carboxymaltose
4. Latest is Iron isomaltoside 1000. 
The newer formulations are less risky and have improved ease of administration.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Iron dextran

A
  • Only preparation that can be injected IM and IV
  • By IM route: absorbed through lymphatics, circulates without binding to transferrin and engulfed by RE cells where iron is made available
  • Not excreted in urine or in bile. •Because dextran is antigenic, anaphylactic reactions are more common
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

IM iron dextran application

A

Given deeply in the gluteal region using Z track technique (to avoid staining of the skin).
Iron dextran can be injected 2 ml daily, or on alternate days, or 5 ml each side on the same day (local pain may occur with the higher dose).
But some part of the dose is locally bound. Thus, 25% extra needs to be added to the calculated dose.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Intravenous iron administration

A
  1. 2 ml containing 100mg iron is injected per day taking 10 min for the injection, or
  2. total calculated dose is diluted in 500 ml of glucose/saline solution and infused i.v. over 6-8 hours under constant observation.
    •Injection should be terminated if the patient complains of giddiness, paresthesias or tightness in the chest.
    •Resuscitation facilities should be available before any iron preparation is injected i.v
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Why is test dose no longer prescribed while giving IV iron supplementation

A

The test dose prescribed earlier is no longer recommended, because the life threatening anaphylactic reaction can occur even when a previous dose or test dose has been well tolerated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

List of oral direct thrombin inhibitors

A
1. Ximelagatran:
Side effect: hepatotoxic
2. Dabigatran:
 Dose reduction in patients with renal failure
 Used as DOAC/ NOAC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Oral factor Xa inhibitors

A
Xa ban:
Apixaban
Edoxaban
Rivaroxaban
Betrixaban
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

NOAC/ DOAC

Explain the properties

A

Novel Oral Anti Coagulants/ Direct acting …
Oral direct thrombin inhibitors + oral factor Xa inhibitors
• monitoring not required (like LMWH, Fondaparinaux)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Uses, ContraIndications and side effects of NOAC/ DOAC

A
Uses:
1. DVT (treatment and prophylaxis)
2. DoC for prophylaxis of thrombosis in non-valvular atrial fibrillation
CI:
1. Mechanical valve thrombosis
2. Antiphospholipid antibodies causing thrombosis
3. Splanchnic vein thrombosis
Side effects: bleeding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Anticoagulant drugs not requiring monitoring

A
Constituents of NOAC/ DOAC:
1. Dabigatran
2. Oral Xa inhibitors
Others:
3. LMWH
4. Fondaparinaux
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Antidote of anticoagulants

A

Against Dabigatran: anti dabigatran monoclonal antibody- Idarucezumab
Against oral Xa inhibitors: Ardexanet-alfa (Xa analogue)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Parenteral direct thrombin inhibitors

A
Hirudin
Semi synthetic:
 Lepirudin
 Desirudin
Synthetic:
 Bivalirudin
 Argatroban
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

The common property of ‘rudins’ of anticoagulants

A

In thrombin they block both catalytic and substrate recognition site
Bivalent direct thrombin inhibitors
(Unlike argatroban, which is a monovalent direct thrombin inhibitor, catalytic site only)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Side effects and contraindications of parenteral direct thrombin inhibitors

A

Side effect: bleeding

CI: renal failure except Argatroban (excreted by liver)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Monitoring of parenteral direct thrombin inhibitors

A

Monitoring aPTT is a must (except Argatroban: both PT and aPTT has to be monitored)

31
Q

Uses of parenteral direct thrombin inhibitors

A
  1. Heparin induced thrombocytopenia (HIT)
    DoC argatroban
  2. DVT- desirudin
  3. STEMI-PCI: bivalirudin
32
Q

Types of indirect thrombin inhibitors

A
  1. Unfractionated heparin UFH
  2. Low molecular weight heparin (enoxaparin, tinzaparin)
  3. Fondaparinaux
33
Q

Properties of unfractionated heparin

A

Glycosaminoglycan= active pentasaccharide + very long chain heteropolysaccharide
From porcine intestinal mucosa
Low bioavailability due to affinity of heteropolysaccharide to various proteins
Lower bioavailability via subcutaneous route (binds proteins at the site of injection)

34
Q

Mechanism of action of unfractionated heparin

A
  1. Active polysaccharide binds to AT-III ➡️ Xa breakdown

2. Heteropolysaccharide HPS binds to IIa ➡️ breakdown of IIa

35
Q

Uses of unfractionated heparin

A
1. Subcutaneous:
 DVT prophylaxis
2. IV:
 Treatment of DVT
Monitoring aPTT is required unlike other indirect thrombin inhibitors due to short t1/2
36
Q

Low molecular weight heparin properties

A
Semi synthetic
Short chain of heteropolysaccharide
Smaller chain prevents binding to large number of IIa 
Xa> IIa inhibition 
Increased bioavailability
37
Q

Low molecular weight heparin examples and uses

A
Enoxaparin
Tinzaparin
Uses (same as Fondaparinaux):
Used via subcutaneous route for treatment and prophylaxis of DVT
Monitoring not required for both
38
Q

Fondaparinaux

A
Synthetic
Only has active pentasaccharide 
Breakdown of Xa only
Highest bioavailability
Uses: same as low molecular weight heparin
39
Q

Metabolism and dosage of indirect thrombin inhibitors

A
1. UFH:
Metabolised by macrophages of RES (short t1/2)
•Safe in renal failure
•Dosage S/C-BD
 IV-QID
2. LMWH and Fondaparinaux:
Excreted unchanged by kidney (longer t1/2)
• CI in renal failure
• S/C dosing- OD
40
Q

DoC for poisoning of indirect thrombin inhibitors

A

Protamine sulphate
Binds to HPS chain and neutralises it
Activity decreases from UFH to Fondaparinaux

41
Q

HIT

A

Ab that cross react to HPS (of heparin and is derivatives) are formed which increases the aggregation of Platelet factor-4 ➡️:
1. Thrombosis:
DoC anticoagulants like DTI, Fondaparinaux,…
2. Thrombocytopenia HIT:
not severe since it is due to consumption not destruction of platelets
More common in:
• females
• post surgical, cancer patients

42
Q

DoC for prophylaxis and treatment of thrombosis

A

LMWH/ Fondaparinaux

For DVT, pulmonary embolism, MI, unstable angina, cancer patients

43
Q

UFH unfractionated heparin is the DoC for

A
  1. Catheter induced thrombosis (factor XII)

2. Concurrent anti coagulation with thrombolysis

44
Q

Side effects of heparin

A

A. Alopecia
H. Hyperkalemia, haemorrhage
O. Osteoporosis
T. Thrombocytopenia (HIT)

45
Q

CI of heparin

A
T. Thrombocytopenia
E. Endocarditis
A. Alcoholics
C. Cirrhosis
H. HTN
E. pEptic ulcer
R. Renal failure
46
Q

Warfarin

A

Inhibitor of VKOR (vitamin K oxidoreductase) which activates vitamin K
Delay in anticoagulant effect in 5 days

47
Q

Warfarin and skin necrosis

A

Warfarin causes skin necrosis by the rapid fall of protein C and S (thrombotic effect) even before anticoagulant effect

48
Q

Sequence of disappearance of clotting factors on warfarin

A

First to disappear: VII
Second to disappear: Protein C
Last to disappear: II

49
Q

Antibiotics and warfarin

A

Antibiotics increases the effect of warfarin by reducing vitamin K synthesis

50
Q

Uses of warfarin

A
  1. Prophylaxis and treatment of DVT:
    Effective only after 5th day
    LMWH given for first 5 days- ‘heparin bridge’
  2. DoC for prophylaxis of thrombosis (mechanical valve)- eg., atrial fibrillation
  3. Antiphospholipid Antibody syndrome
51
Q

Side effects of warfarin

A
Bleeding
Worsens HIT
Alopecia
Skin necrosis (M/C in breast of female)
Teratogenic (nasal hypoplasia, stippled epiphyseal calcification)- decreased osteocalcin (vit K is decreased)
52
Q

Warfarin in pregnancy

A

Warfarin is not used in pregnancy due to teratogenic effects (nasal hypoplasia, stippled epiphyseal calcification)- decreased osteocalcin (vit K is decreased)
Except for mechanical valve thrombosis:
Crosses placenta ➡️ Increases risk of intraventricular haemorrhage ➡️ stopped at 36th week ➡️ continue with LMWH

53
Q

Monitoring of warfarin

A

Low therapeutic index ➡️ PT/INR is monitored
Normal INR: 0.9-1.3
Target: 2-3 for warfarin
1. Between 3-10 and asymptomatic ➡️ stop warfarin ➡️ restart when INR is normal
2. >10 and asymptomatic ➡️ stop warfarin and give vit K (2.5-5 mg oral)
3. Symptomatic➡️ stop warfarin ➡️ start FFP + IV Vitamin K (5-10 mg)

54
Q

Streptokinase

A
  • Binds to plasminogen ➡️ uncovers tpa binding site ➡️ increases plasmin
  • High dose requirement because of streptococcus antibodies
  • Clot non specific drug ➡️ high risk of bleeding
  • Transient hypotension (bradykinin)
55
Q

tpa analogues

A
Alteplase
Reteplase
Duteplase 
Tenecteplase - maximum clot specificity (rather than plasma fibrin)
Lesser risk of bleeding
56
Q

Uses of tpa analogues or fibrinolytics

A
  1. Thrombolysis:
    STEMI, ischemic stroke
  2. Massive pulmonary embolism (more powerful)
  3. Local route for peripheral thrombosis
57
Q

CI of tpa analogues

A
B. Brain tumour/ aneurysm
R. Recent stroke/ trauma
A. Aortic dissection
I. Intracranial haemorrhage history
N. Non competitive vascular punctures
58
Q

Side effects of fibrinolytics

A

Bleeding
DoC for fibrinolytic induced bleeding: EACA- an antifibrinolytic (Epsilon amino caproic acid)
Transexemic acid (anti fibrinolytic) can also be used

59
Q

Uses of anti fibrinolytics like EACA

A
  1. DoC for fibrinolytics induced bleeding
  2. Gastric ulcer bleed
  3. Variceal esophagial bleed
    Transexemic acid is also an anti fibrinolytic
60
Q

Factors involved in platelet aggregation which are utilised pharmaceutically

A
  1. GPIIb/IIIa: adhesion of platelets
  2. TxA2
  3. ADP stimulates P2Y12 receptor
  4. Phospholipids activates coagulation system
61
Q

Aspirin as an antiaggregant

A

Irreversible inhibitor of COX-2 ➡️ decreases TxA2
Low dose ➡️ 50-325 mg OD
Side effects: bleeding
Continued in case of surgery (unlike clopidogrel)

62
Q

Uses of aspirin

A
  1. Acute coronary syndrome (MI, unstable angina)

2. 2° prophylaxis of MI and stroke

63
Q

Classification of ADP/ P2Y12 receptor inhibitors

A
1. Irreversible (prodrugs):
 Clopidogrel
 Ticlopidine
 Prasugrel
2. Reversible:
 Competitive: Cangrelor
 Non competitive:Ticagrelor
64
Q

Hit and run drugs

A

Drugs acting longer than t1/2 due to irreversible binding to their target
Eg., clopidogrel

65
Q

Clopidogrel

A

ADP/ P2Y12 receptor inhibitor
Uses (like aspirin):
1. 2° prophylaxis of MI and stroke (along with aspirin for stent placement post MI)
2. Acute coronary syndrome- MI/ unstable angina

66
Q

Ticlopidine

A
Most toxic ADP/ P2Y12 receptor inhibitor
Not preferred
Effects:
1. GIT upset- nausea, vomiting 
2. Agranulocytosis
3. Thrombocytic purpura - haemolytic uremic syndrome complex
67
Q

Prasugrel

A

Fastest and most effective ADP/ P2Y12 receptor inhibitor
CI:
High risk of intracranial bleed ➡️ CI in cerebrovascular diseases
Uses (similar to Cangrelor):
STEMI - percutaneous intervention (PCI)

68
Q

Cangrelor

A
Adenosine analogue
Competitive inhibitor of ADP/ P2Y12 receptor
t1/2 is 3-6 min only
IV short acting
Uses:
STEMI - PCI (same as prasugrel)
69
Q

Ticagrelor

A

Long acting ADP/ P2Y12 receptor inhibitor
Can be given orally
Uses:
Acute coronary syndrome- MI, unstable angina (along with aspirin/ clopidogrel)

70
Q

Varapaxar

A

Protease activated receptor (involved in aggregation) inhibitor
Side effect:
Risk of cranial bleed ➡️ CI in cerebrovascular disorders (like prasugrel)
Uses:
1. 2° prophylaxis of acute coronary syndrome (along with aspirin/clopidogrel)
2. Prophylaxis of peripheral arterial disease

71
Q

GP IIb/ IIIa inhibitors examples and uses

A
  1. Abciximab
  2. Tirofiban
  3. Eptifibatide
    Uses:
  4. Acute coronary syndrome
  5. Acute attack of stroke (ischemic)
72
Q

Abciximab

A

GP IIb/ IIIa and vitronectin inhibitor ➡️ more effective
Side effect:
bleeding and thrombocytopenia
Shortest t1/2 but has maximum affinity so longest acting

73
Q

Eptifibatide

A

GP IIb/ IIIa inhibitor
Longest t1/2 (minimum affinity)
Shortest acting